top of page
Browse by category
Search


High cost or insurance-related issues are the most common reasons for discontinuation with semaglutide or tirzepatide
High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for...


EASO recommends semaglutide and tirzepatide as first-line treatment for obesity
Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to...


Taking semaglutide reduces ‘food noise’
Individuals who are taking semaglutide for weight loss experience less food noise than before, according to research presented at the...


Semaglutide cuts risk of heart attack, stroke or death by 57% vs tirzepatide
Outcomes form the STEER real-world study have revealed that semaglutide 2.4 mg had 57% greater risk reduction for heart attack, stroke...


Consuming more protein may protect semaglutide patients taking from muscle loss
Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help...


Semaglutide effective for people with schizophrenia
Diabetic weight-loss medications are effective for people with schizophrenia without affecting psychotic symptoms, according to...


Semaglutide associated with double risk of neovascular macular degeneration
Semaglutide is associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older...


COURAGE Trial confirms potential to improve the quality of semaglutide-induced weight loss by preserving lean mass
Interim results from the ongoing Phase 2 COURAGE trial - investigating novel combinations of semaglutide (GLP-1 receptor agonist) and...


Brain nerve cells control the beneficial effects of semaglutide
Researchers at the Sahlgrenska Academy at the University of Gothenburg have shown that it is possible to distinguish the nerve cells in...


SURMOUNT-5: Tirzepatide shows superior weight loss over semaglutide
Seventy-two week outcomes from the SURMOUNT-5 clinical trial have shown that tirzepatide (Zepbound) met the primary endpoint and all five...
Browse by tag






bottom of page

